tests in apple-allergic patients (n = 2) confi rmed the markedly decreased ability of the Mal d 1 mutant to induce allergic reactions in vivo. However, the relevant T cell epitopes were present in the mutated molecule according to peripheral blood mononuclear cell proliferation assays. Conclusions: Our fi ndings suggest that it is possible to modulate the IgE-binding properties of allergens by single amino acid substitutions at crucial positions which might be useful for future immunotherapy of birch-pollen-associated food allergies which are not ameliorated by birch pollen immunotherapy.
Introduction
Patients suffering from allergy to birch pollen often develop allergic reactions after ingestion of various fruits (e.g. apple, pear, peach, cherry), nuts (e.g. hazelnut, walnut), and vegetables (e.g. celery, carrot, potato) [1] [2] [3] . The major birch pollen allergen, Bet v 1, and its corresponding homologues in these foods could be identifi ed as the cross-reactive molecules mainly responsible for this form of food allergy [4] [5] [6] [7] [8] . The deduced amino acid sequence of Mal d 1, the major apple allergen, shows 55% identity to Bet v 1a (EMBL, Genbank Database access No. X15877; [7, 9] ). Cross-inhibition experiments demonstrated that recombinant Mal d 1 shares IgE epitopes with Bet v 1a [7] . In addition, Mal d 1 also shares T cell epitopes with the major birch pollen allergen, Bet v 1 [10] . This homology is also refl ected by the clinical observation that apple allergy starts after the onset of birch pollinosis [4, [10] [11] [12] . The hypothesis suggests that Bet v 1 sensitization initiates allergic reactions to Mal d 1.
Therefore, one would assume that successful birch pollen specifi c immunotherapy (SIT) should also ameliorate the symptoms of concomitant apple allergy. However, this issue is still controversial, and studies supporting as well as contradicting this hypothesis were published [13] [14] [15] .
Previously, we proposed a new concept for the development of vaccines for SIT. Using site-directed mutagenesis, allergen variants were engineered that display signifi cantly reduced allergenicity in terms of IgE binding and thus reducing the risk of developing anaphylactic reactions upon injection. On the other hand, these allergen mutants are still recognized by T helper cells and can therefore modulate the allergic immune response at the T cell level, a characteristic shown to be essential for successful immunotherapy [16] [17] [18] .
Our approach was validated using the Bet v 1 molecule and introducing six-point mutations at critical positions. The resulting molecule was still recognized by allergenspecifi c T lymphocytes, but displayed signifi cantly reduced IgE binding capacity, as determined by in vivo and in vitro tests [19] .
In the present study we investigated whether the amino acid residues/positions shown to be involved in the formation of IgE-binding epitopes of Bet v 1 are also crucial for IgE recognition of Mal d 1, the homologous allergen from apple. This was tested using a PCR-based sitedirected mutagenesis approach to produce a Mal d 1mu-tant protein and to evaluate whether it would represent a candidate for SIT in pollen-related apple allergy.
Materials and Methods

DNA Constructs
The cDNA coding for Mal d 1.0108 (EMBL Genbank Database access No. AJ417551) was cloned into the pMW172 expression vector [20] as previously described [7, 21] . The fi ve-point Mal d 1 mutant was generated using the three-primer PCR mutagenesis method [19] The oligonucleotides were obtained from MWG Biotech AG (Ebersberg, Germany), restriction enzymes from MBI Fermentas GmbH (St. Leon-Rot, Germany) and all the other chemicals used were purchased from Sigma-Aldrich Chemie (Sleinheim, Germany).
Internal Mutagenic Primers
M30 5 -AATCTTGGGGAcGAGGTTGTC-3 ; M57 5 -TTCACCAAAAtTGATCTTCTTG-3 ; M112 + 113 5 -GTGGTTCCtgCgTCAAGAGCATC-3 . The exchanged bases are in dicated in lower case. For mutation at position 10: M10: 5 -GGGCATATGGGTGTGTACACCTTCGAGAACGAGTTCcCCTCTG-3 ; Flanking primers: Nde I (underlined) 5 -GGGCATATGGGTGTGTACA-CC TTCGAG-3 and EcoR I (underlined) 5 -CAAGGAATTC-TTAGTTGTAGGCATCCGGGTGGTCCTT-3 .
The PCR products were digested with Nde I and EcoR I and subcloned in expression vector pMW172. Competent Escherichia coli BL21 cells were transformed with the resulting plasmids.
In the following Mal d 1.0108 will be referred to as Mal d 1 wildtype (Mal d 1wt) and the engineered mutant thereof as Mal d 1 mutant (Mal d 1mut).
Expression and Preparation of E. coli Cell Lysates of Allergen Wild Types and Mutants
A single transformant colony of pMW172/Mal d 1wt and pMW172/Mal d 1mut, respectively, was picked and grown in LB/100 mg/l ampicillin under constant shaking at 37 ° C to an OD 600 of 1.0. Expression of recombinant proteins was induced and harvested as described previously [22] .
Insoluble inclusion bodies containing rMal d 1wt and rMal d 1mut were solubilized in buffer A (20 m M imidazole, pH 7.4/4% isopropanol) containing 6 M urea and dialyzed stepwise against buffer A with decreasing urea concentrations (4 M , 2 M, 1 M, 0.5 M ) and fi nal buffer A at 4 ° C (dialysis tubes -Spectra/Por Membrane with MWCO of 10,000, Medicell International Ltd, London, UK). Subsequently, the extracts were subjected to further purifi cation by DEAE chromatography applying a 10 ! 100 mm column packed with DEAE-Sepharose Fast fl ow (Amersham, Biosciences, Little Chalfont, UK). A linear gradient was performed (buffer A: 20 m M imidazole pH 7.4/4% isopropanol; buffer B: buffer A/ 250 m M NaCl; gradient 0-100%) within 100 ml. Afterwards, the proteins were purifi ed by separation over a phenyl cellufi ne column (10 ! 100 mm; Biorad, Hercules, Calif., USA; buffer A: 0.8 M NaCl/15 m M NaH 2 PO 4 /10 m M acetic acid pH 4.5; gradient 0-100% B within 100 ml. Fractions were checked by SDS-PAGE analysis and the pure protein fractions pooled and lyophilized.
Purifi ed recombinant Bet v 1a [EMBL, Genbank Database accession No. X15877, referred to here as Bet v 1 wild-type (Bet v 1wt)] and Bet v 1 mutant (Bet v 1mut [19] ) were purchased from Biomay (Vienna, Austria). All recombinant allergens were tested for bacterium-derived endotoxin levels using a limulus amoebocyte lysate assay according to the manufacturer's instructions (Bio Whittaker, Verviers, Belgium).
Structural Models of Bet v 1 and Mal d 1
The 3D model of Mal d 1 was produced by Swiss Model software [23] using the structure of Bet v 1 as a template (PDB code: 1BV1) and the sequence alignment of Bet v 1a and Mal d 1.0108 ( fi g. 1 a).
N-Terminal Sequencing
Fifty picomoles of purifi ed rMal d 1wt and rMal d 1mut, respectively, were immobilized on polyvinylidene difl uoride (PVDF) membranes (ProSorb sample preparation cartridges, Applied Biosystems, Foster City, Calif., USA) and analyzed as described [22] . For mass measurements, 0.5 l (approximately 0.5 g) of reduced and alkylated rMal d 1wt and rMal d 1mut proteins were analyzed with the Kompact MALDI IV mass spectrometer (Kratos Analytical, Manchester, UK) in the linear fl ight mode as described previously [24] .
Circular Dichroism Spectra
Circular dichroism (CD) measurements of purifi ed rMal d 1wt and rMal d 1mut (0.15 g/ l) were performed in aqueous solutions using a Jasco J-810 spectropolarimeter (Japan Spectroscopic Co., Tokyo, Japan) fi tted with an RTE-111M temperature control system (Nes-Lab) as described previously [25] . 
Patients and Sera
Within a study funded by the European Commission Framework 5, apple-allergic patients were selected in the Netherlands and Austria. Dutch patients were recruited at the Department of Dermatology/Allergology of University Medical Centre Utrecht and the Austrian patients at the Medical University of Vienna. All the patients reported immediate adverse reactions to apple ingestion and the inhalation of birch pollen together with a positive skin prick test (SPT) to fresh Golden Delicious apples. According to EAACI recommendations [26] , SPT was considered positive if the wheal area was 7 mm 2 (3 mm diameter) greater than the negative control. Furthermore, the sera selected for this study (n = 30) displayed a positive RAST to apple ( 1 3.5 IU/ml) as well as to Mal d 1 ( 1 1.8 IU/ml). Sera from healthy donors (n = 5) with negative case histories, negative SPT, and negative RAST were used as controls. The study was performed with the approval of the local ethics committees and with the patients' consent (or their legal representatives' consent).
SDS-PAGE, IgE Immunoblots and ELISA
Purifi ed rMal d 1wt, rMal d 1mut, rBet v 1wt, and rBet v 1mut
were subjected to 15% SDS-PAGE (2 g/lane) [27] performed under reducing conditions and either visualized by Coomassie Brilliant Blue R-250 staining or further electroblotted onto nitrocellulose membranes [28] . The IgE-binding abilities of the purifi ed recombinant proteins were detected applying sera from food-allergic patients (1: 5 diluted in 50 mmol/l sodium phosphate buffer/0.5% Tween 20/1% BSA pH 7.5) according to established protocols [29] . Bound IgE was detected by 125 I-labelled antihuman IgE antibodies (1: 20 dilution; MALT Allergy System Isotope Reagent, IBL, Hamburg, Germany) and visualized by autoradiography. In parallel, the serum pool from 5 non-allergic subjects and buffer were used as controls.
For ELISA experiments the same set of proteins (10 g/ml) was dissolved in 25 m M NaHCO 3 , pH 9.6 and coated on microtitre wells (Nunc Maxisorp, Nalge Nunc International, Roskilde, Denmark) overnight at 4 ° C. Non-specifi c binding sites were blocked with 2% milk in TBS/0.05% Tween 20 (v/v). Coated protein was incubated with sera from apple-allergic patients (1: 5 dilution) overnight at 4 ° C. Bound IgE from 14 apple allergic sera (No. 10-23) was detected with alkaline-phosphatase-conjugated mouse antihuman IgE antibody (1: 1,000; BD-Biosciences Pharmingen, San Diego, Calif., USA) and developed with the p -nitrophenyl phosphate substrate. Colour development was measured using an ELISA reader (Spectra Max Plus 384; Molecular Devices GmbH, Munich, Germany) at 405 nm and 510 nm as reference wavelength. Optical density (OD) values from normal human serum (n = 5) samples were obtained and standard deviation calculated. All OD values from serum samples above mean value plus 3 standard deviations were considered positive.
Titration SPT
After obtaining written consent, SPT were performed in 2 apple-allergic patients on the fl exor aspect of the forearm with fresh apple (Golden Delicious) and rMal d 1wt and rMal d 1mut using a standardized prick needle (ALK-Lancet, Horsholm, Denmark [26, 30] ). Allergen concentrations of 0.02, 0.2, 2, 20 and 100 g/ml were applied and SPT reactivity was measured after 15 min by copying the wheal reaction with transparent adhesive tape onto a record sheet. Subsequently, the wheal area was determined by computer scanning [31] . Histamine dihydrochloride (10 mg/ml) was used as a positive control, and the glycerol containing diluents of the SPT extract was used as a negative control (ALK-Abelló, Nieuwegein, The Netherlands). SPT responses were standardized by dividing the original wheal area following a prick by that obtained for the histamine control; a relative wheal area of at least 0.25 SPT/histamine, which is comparable to a reaction of 1 1+ by the standard procedure [26, 31] , was considered positive.
Proliferation Assays
and 25 g/ml) were evaluated as described previously [32] . 
Results
Sequence Analysis and Structural Modelling
Recombinant Mal d 1wt and rMal d 1mut were produced according to established protocols. The fi ve-point mutations for Mal d 1mut
Expression, Purifi cation, and Characterization of rMal d 1wt and rMal d 1mut
Production in E. coli yielded 80 mg purifi ed recombinant Mal d 1wt and 40 mg purifi ed Mal d 1mut per litre culture, respectively. The proteins appeared as homogeneous single bands migrating at 17 kDa as determined by SDS-PAGE and Coomassie staining (data not shown). N-terminal analysis of both purifi ed proteins revealed that the initiating methionine was cleaved off, resulting in the fi rst fi ve amino acid residues: GVYTF (data not shown) corroborating that the initiating methionine was cleaved off according to the side chain length of the penultimate amino acid [33] .
The integrity of the primary structure was further verifi ed by MALDI-TOF mass spectrometry analysis. The molecular weight of reduced and alkylated rMal d 1wt and rMal d 1mut proteins was measured as 17,556.65 (theoretical 17,549.72) and 17,576.87 (theo-retical 17,589.76), respectively. Analysis for endotoxin levels yielded 0.23 EU/ g protein for purifi ed rMal d 1wt and 0.08 EU/ g protein for rMal d 1mut. These values are below the threshold values allowed for human therapeutics for parenteral application (e.g. Austrian threshold level: 8 EU/ml).
CD spectra of rMal d 1wt and rMal d 1mut showed that the preparations consisted of folded proteins and that the overall secondary structure content of the two proteins was very similar ( fi g. 2 ). On heating to 95 ° C, the spectra of rMal d 1mut changed to that of a random coil ( fi g. 2 b), as usually observed with polypeptides undergoing thermal unfolding. However, rMal d 1wt was not completely denatured after heating to 95 ° C ( fi g. 2 a). Upon cooling to 25 ° C, rMal d 1wt showed a CD spectrum similar in shape and peak amplitudes to the one recorded before heating, suggesting that rMal d 1wt is able to correctly refold after thermal denaturation. In contrast, thermally denatured rMal d 1mut was only able to partially refold. 
Infl uence of Amino Acid Substitutions on Antibody Binding
To evaluate the antibody-binding properties of the engineered proteins compared to the corresponding wildtypes, we performed immunoblotting experiments.
Sera from 9 apple-allergic patients ( fi g. 3 , lanes 1-9) were tested in immunoblots for IgE recognition of rMal d 1mut ( a , b , left) , and rBet v 1wt and rBet v 1mut ( a , b , right) were tested with 9 serum samples derived from apple-allergic patients (lanes 1-9) rBet v 1mut as it has previously been shown for rBet v 1 and rApi g 1 ( fi g. 3 a, lanes 2, 5, 9 for rMal d 1wt, lanes 2, 5, 8, 9 for rBet v 1wt and lanes 5, 9 for rBet v 1mut [34] [35] [36] ) . IgE reactivity to rMal d 1wt was less strong compared to the IgE reactivity to rBet v 1wt. In 7 out of 9 sera, IgE reactivity to rMal d 1mut and rBet v 1mut was clearly reduced ( fi g. 3 , lanes 1-4, 6-8). For controls, either normal human serum pool or buffer was used and was negative in all experiments ( fi g. 3 a, b, lanes 10-11).
The IgE binding activities of rMal d 1wt, rMal d 1mut, rBet v 1wt, and rBet v 1mut were also tested by ELISA using sera from 14 apple-allergic patients. Both proteins induced comparable T cell proliferations upon addition of the recombinant proteins.
Discussion
In this study we could demonstrate that the amino acid positions involved in the formation of IgE-binding epitopes previously shown for Bet v 1 [19] are also important for Mal d 1, the major apple allergen.
Mal d 1 consists of a number of isoforms [37] but, in contrast to Bet v 1 isoforms [38] , no signifi cant differences in IgE-binding activity for individual naturally occurring Mal d 1 isoforms could be identifi ed [37] . We have chosen Mal d 1.0108 (EMBL Genbank Database accession No. AJ417551), identical to Mal d 1a at the amino acid level (clone GD26 from Golden Delicious, EMBL Genbank Database accession No. AF126402 [37] ) as the wild type (Mal d 1wt), and obtained a Mal d 1 mutant (Mal d 1mut) by site-directed mutagenesis. Both sequences were expressed in E. coli and purifi ed to homogeneity by chromatographic procedures. The integrity of the primary structure of the purifi ed proteins was evaluated by mass spectrometry. Our CD spectroscopy experiments showed that the overall secondary structure contents of Mal d 1wt and Mal d 1mut were very similar. Thus, it seems that the amino acid substitutions did not cause major disturbances in the protein fold and structural characteristics.
Interestingly, the introduced mutations changed the thermostability of Mal d 1. In contrast to rMal d 1wt, rMal d 1mut did not completely refold after heating to 95 ° C. Based on statistical examination of structural and sequence parameters infl uencing thermostability of proteins preferred and avoided residues in thermophilic proteins can be identifi ed [39] . In this context the Asn57 and Cys112 exchange as well as the Thr10Pro and Ile30Val exchange contribute to an overall decrease in the thermostability of rMal d 1mut [40, 41] .
The IgE binding capacity of rMal d 1wt, rMal d 1mut, rBet v 1wt, and rBet v 1mut was tested in immunoblots using sera from allergic patients. In addition to the major band migrating at 17 kDa, an additional, fainter band around 34 kDa was detected by specifi c IgE by the more sensitive IgE immunoblot. Bet v 1 and homologous proteins tend to form dimers as has been shown for Bet v 1 and Api g 1 previously [34] [35] [36] . Six out of 9 sera showed decreased binding to rMal d 1mut when compared to rMal d 1 wt. This was also the case when testing rBet v 1wt and rBet v 1mut.
Performing IgE ELISA, the majority of another set of patients' sera (10/14) tested showed a decrease by 88-30% in IgE binding to rMal d 1mut compared to rMal d 1wt. This effect was reduced in three serum samples (decrease by 13%) and was not observed in one sample that displayed also no difference when testing IgE binding to rBet v 1wt and rBet v 1mut. Again in the case of rBet v 1wt, the decrease in IgE binding was more pronounced compared to rMol d 1wt.
It [42] .
The in vitro data revealed that IgE binding to rMal d 1mut was decreased by 88-13% compared to IgE binding to rMal d 1wt depending on the serum samples used. However, in in vivo tests the hypoallergenic nature of rMal d 1mut was demonstrated by skin prick testing of 2 apple-allergic patients. Compared to rMal d 1wt, rMal d 1mut showed a strongly reduced (50-82%) capacity to induce typical skin reactions. These results are in good agreement with other in vivo tests performed with rMal d 1wt and rMal d 1mut by Bolhaar et al. [44] .
In contrast, both recombinant allergens, rMal d 1wt and rMal d 1mut were able to activate and induce proliferation of allergen-specifi c T cells from apple-allergic patients.
So far, relevant IgE epitopes have been determined from the cherry homologue, Pru av 1 [45] another Bet v 1 homologous food allergen. Similar to Bet v 1, the socalled p-loop was identifi ed as a crucial B-cell epitope in Pru av 1 [46] . A second epitope has recently been described by Wiche et al. [47] , who showed that amino acid position 28 was crucial for this epitope which is located in the helix 2 area and is clinically relevant to pollen fruit cross-reactivity. Despite different amino acid positions, these fi ndings are in agreement with our point mutation of Ile30Val in Mal d 1mut since they are all part of the same secondary structure motif.
Although these reports clearly point to hot spots critical for IgE binding, no linear epitopes on Bet v 1 have been identifi ed so far. Thus, the conserved overall 3D structure of the protein seems to be a prerequisite for IgE binding. If the structure is disrupted, a dramatic reduction of either IgE binding or IgE-dependent reactions can be observed. This was shown by the single amino acid exchange Ser 112 of Pru av 1 by Neudecker et al. [46] that resulted in an unfolded protein [46] . The recombinant trimer of Bet v 1 displaying a reduced IgE binding capacity and in vivo allergenic activity is another example of the concept of unfolded or not properly folded proteins [48] . It remains to be established on a whole range of proteins whether the concept of unfolded/misfolded denatured proteins as postulated by Crameri [49] or the theory of point-mutated proteins targeting the major IgE epitopes is the method of choice for developing hypoallergenic vaccines for SIT for the benefi t of the vast majority of allergic patients.
In conclusion, the results presented here showed that it is possible to decrease the IgE-binding affi nity of epi topes by single amino acid substitutions at crucial positions. Recombinant Mal d 1mut carrying 5-amino-acid substitutions showed decreased allergenicity in vitro and in vivo and conserved antigenicity in terms of T cell recognition when testing a number of apple-allergic patients. Our experiments also showed that these 5-amino-acid substitutions affected the overall IgE recognition of Mal d 1. In cases where birch pollen immunotherapy based on Bet v 1 desensitization fails to ameliorate the associated Mal d 1-induced food-allergic symptoms, the concept of mutated hypoallergenic food allergens seems to offer new possibilities. Furthermore, there is a need in the food allergic population to eat the offending food again but without concomitant symptoms, since the allergic consumers want to extend their daily diet and to intake fresh fruit together with vitamins. This has been investigated by a consumer survey across Europe [50] . Thus, the Mal d 1mut described here can serve as template for engineering a hypoallergenic vaccine for apple-allergic patients. Injection of such engineered hypoallergens for immunotherapy could modulate the allergic immune response at the level of the T helper cell, but with a substantially decreased risk of anaphylactic (IgE-mediated) side effects during treatment.
